Profile data is unavailable for this security.
About the company
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
- Revenue in USD (TTM)68.00k
- Net income in USD-52.32m
- Incorporated2014
- Employees23.00
- LocationCheckpoint Therapeutics Inc95 SAWYER ROAD, SUITE 110WALTHAM 02453United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (302) 531-3150
- Websitehttps://checkpointtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LAVA Therapeutics NV | 6.77m | -41.97m | 70.98m | 37.00 | -- | 1.39 | -- | 10.49 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.76m | 72.65m | 17.00 | -- | 3.52 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Alpha Teknova Inc | 36.85m | -36.06m | 73.07m | 210.00 | -- | 0.8764 | -- | 1.98 | -1.05 | -1.05 | 1.05 | 2.04 | 0.2815 | 2.29 | 7.89 | 175,490.50 | -27.54 | -- | -29.30 | -- | 27.36 | -- | -97.85 | -- | 3.92 | -28.23 | 0.1365 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| Marinus Pharmaceuticals Inc | 28.29m | -145.34m | 74.16m | 165.00 | -- | -- | -- | 2.62 | -2.64 | -2.64 | 0.5142 | -0.2992 | 0.1554 | 0.8536 | 3.72 | 171,442.40 | -79.82 | -49.64 | -96.93 | -57.76 | 91.22 | -- | -513.80 | -518.96 | 2.93 | -13.62 | 1.29 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| Instil Bio Inc | 0.00 | -123.32m | 74.40m | 49.00 | -- | 0.3615 | -- | -- | -18.96 | -18.96 | 0.00 | 31.65 | 0.00 | -- | -- | 0.00 | -33.63 | -- | -35.47 | -- | -- | -- | -- | -- | -- | -- | 0.2841 | -- | -- | -- | 30.06 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -23.72m | 74.46m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
| Checkpoint Therapeutics Inc | 68.00k | -52.32m | 74.81m | 23.00 | -- | -- | -- | 1,100.09 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Personalis Inc | 74.15m | -92.61m | 75.83m | 223.00 | -- | 0.6217 | -- | 1.02 | -1.89 | -1.89 | 1.51 | 2.35 | 0.3172 | 6.50 | 5.04 | 332,493.30 | -39.62 | -28.84 | -46.08 | -34.72 | 25.59 | 28.65 | -124.90 | -96.01 | 3.56 | -- | 0.0209 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| MDxHealth SA - ADR | 75.33m | -39.90m | 77.50m | 300.00 | -- | -- | -- | 1.03 | -1.14 | -1.14 | 0.8428 | -0.0357 | 0.5528 | 11.06 | 6.95 | 251,090.00 | -29.28 | -51.62 | -33.98 | -64.72 | 62.76 | 50.88 | -52.97 | -117.64 | 1.53 | -1.71 | 1.02 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Earth Science Tech Inc | 5.98m | 330.94k | 78.71m | 8.00 | 260.42 | 36.47 | 148.72 | 13.15 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| BioXcel Therapeutics Inc | 1.76m | -153.05m | 78.81m | 74.00 | -- | -- | -- | 44.88 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 79.38m | 9.00 | -- | 4.02 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Aileron Therapeutics Inc | 0.00 | -18.07m | 79.67m | 15.00 | -- | 1.39 | -- | -- | -3.19 | -3.19 | 0.00 | 5.42 | 0.00 | -- | -- | 0.00 | -31.05 | -65.99 | -33.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Data as of May 21 2024. Currency figures normalised to Checkpoint Therapeutics Inc's reporting currency: US Dollar USD
13.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 2.72m | 7.76% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 915.86k | 2.62% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 271.22k | 0.78% |
| Geode Capital Management LLCas of 31 Mar 2024 | 198.50k | 0.57% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 162.28k | 0.46% |
| Securities America Advisors, Inc.as of 31 Mar 2024 | 134.63k | 0.39% |
| PVG Asset Management Corp.as of 31 Dec 2023 | 115.37k | 0.33% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 108.61k | 0.31% |
| Legacy Wealth Asset Management LLCas of 31 Mar 2024 | 85.00k | 0.24% |
| Envestnet Asset Management, Inc.as of 31 Mar 2024 | 76.64k | 0.22% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
